Akebia Therapeutics (AKBA) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 4.5% versus a loss of 70.4%. Over five years, LFCR leads with a -34.4% price change compared with -69.4% for AKBA. Lifecore Biomedical is the larger company by market cap ($243.7 million vs $232.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | LFCR |
|---|---|---|
| Share price | $0.8386 | $6.43 |
| Market cap | $232.38M | $243.73M |
| 1-day change | -3.98% | -0.16% |
| YTD return | -45.75% | -21.27% |
| 1-year return | -70.39% | -4.45% |
| 5-year return | -69.35% | -34.35% |
| EPS (TTM) | $-0.12 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $8.98 |
| 52-week low | $0.814 | $3.63 |
| Distance from 52-week high | -73.79% | -28.40% |
| Analyst consensus | none | hold |
| Avg. price target upside | +367.45% | -2.33% |
| Average volume | 6.13M | 289.19K |
| Shares outstanding | 277.11M | 37.91M |
| Employees | 194 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed AKBA by 65.9 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
AKBA vs LFCR FAQ
Which is bigger, Akebia Therapeutics or Lifecore Biomedical?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $243.73M compared with $232.38M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or LFCR?
LFCR returned -4.45% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.